Objectives Venous thromboembolism (VTE) is the third most common acute cardiovascular
disease. VTE includes both pulmonary embolism (PE) and deep vein thrombosis (DVT) and …

Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE)
and deep vein thrombosis (DVT), is the third most common acute cardiovascular disease …

Objectives The National Institute for Health and Care Excellence in the United Kingdom (UK)
recently issued guidance recommending the non-vitamin k antagonist oral anticoagulants …

抄録< jats: title> Summary</jats: title>< jats: p> Direct oral anticoagulants simplify venous
thromboembolism (VTE) treatment by obviating the need for coagulation monitoring …

Objectives This study estimated the cost-effectiveness of novel oral anticoagulants for (i)
acute treatment and (ii) secondary prevention, of VTE from the perspective of the NHS …

Objectives Edoxaban and rivaroxaban are both once daily oral anticoagulants that have
shown non-inferiority in terms of safety and efficacy versus warfarin without the need for …

Objectives This evaluation aimed to assess the cost-effectiveness of edoxaban 60mg versus
warfarin for the prevention of stroke and systemic embolic events among patients with non …

Direct oral anticoagulants simplify venous thromboembolism (VTE) treatment by obviating
the need for coagulation monitoring. Nonetheless, renal function, body weight and P …

Background Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and
pulmonary embolism [PE]) has an annual incidence rate of 104–183 per 100,000 person …

Objectives This study aimed to determine the cost-effectiveness of Edoxaban versus low-
molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) from the US healthcare …